<DOC>
	<DOCNO>NCT00951275</DOCNO>
	<brief_summary>This single arm study assess effect tocilizumab + DMARDs ( Disease Modifying Anti-Rheumatic Drugs ) improvement anemia fatigue patient moderate severe active rheumatoid arthritis . Eligible patient inadequate response DMARDs receive tocilizumab 8mg/kg iv every 4 week combination standard DMARDs , 6 month . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tocilizumab + DMARDs Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; rheumatoid arthritis &gt; =6 month duration ; DAS28 &gt; =3.2 ; inadequate response prior treatment stable dose ( &gt; =8 week ) DMARD therapy . rheumatic autoimmune disease rheumatoid arthritis ; history current inflammatory joint disease rheumatoid arthritis ; unsuccessful treatment antiTNF agent ; previous/concurrent treatment celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>